Immune response to the terminal repeat protein of epstein-barr virus in patients with undifferentiated nasopharyngeal carcinoma

Screening of 205 patients suffering from various diseases and healthy donors for the presence of serum antibodies to terminal repeat protein (TP) of Epstein-Barr virus was carried out using the indirect immunofluorescence technique. TP antibodies were detected exclusively in patients with undifferentiated nasopharyngeal carcinoma (in 30–40% of patients within this group). Evaluation of TP antibody titers before and after treatment revealed a correlation between the dynamics of these antibodies and the clinical prognosis of patients.